Neal D. Shore, MD, FACS - Changing the Treatment Story With Hormonal Therapy in Prostate Cancer: Challenges and Opportunities for Improving Care Across Disease Settings

Go online to PeerView.com/QAT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in urologic oncology discusses hormonal therapy in prostate cancer. Upon completion of this activity, participants should be better able to: Summarize the recent safety and efficacy data on novel hormonal therapy for metastatic castration-sensitive prostate cancer (mCSPC), as well as for other prostate cancer settings including castration-resistant (nmCRPC and mCRPC) disease, Counsel patients on current hormonal therapy standards for personalized management of prostate cancer, including for treatment selection based on disease progression, prior therapy, and patient characteristics, Design individualized, evidence-based treatment plans for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors, Manage the spectrum of adverse events associated with novel hormonal therapies in patients with prostate cancer.